Amgen: MariTide Underwhelms, But There Are Ways To Win
Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.
Why Amgen’s MariTide could rival Eli Lilly, Novo Nordisk’s obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...
BioPharma Dive8d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
Amgen decline on MariTide data could be due to lack of more details
Two Street analysts weigh in on Amgen's phase 2 MariTide data, saying that they would like to see additional details on the ...
MM&M8d
Amgen’s MariTide achieves 20% weight loss, but Wall Street remains unimpressed
Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...
BioSpace8d
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...
Wall Street awaits Amgen weight-loss drug data expected to move shares
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...